Forward-looking statements in this press release include, without limitation, statements regarding the promise and potential impact of our product candidates, including Revitas potential for preserving weight loss after GLP-1 drug discontinuation
Some of the examples include Structure Therapeutics, Viking Therapeutics, AstraZeneca, and Merck & Co., Inc
His testimonial reinforces ColonBroom's versatility, it can serve both those seeking weight control and those optimizing performance
Giblin et al., Diabetes Obes Metab 2026 (trial design paper) Note: Some media reports cite NCT05869903 for TRIUMPH-4
Reconstitution Support and Documentation Look for product-level notes on recommended solvent, storage, and stability